(Press-News.org) A new, multinational randomized clinical trial has found that patients with severe and enduring anorexia nervosa will not only stick with treatments but also make significant improvements with just a slight modification of the standard goals and methods of treatment.
More than 85 percent of those who enrolled in the trial completed treatment—almost three times the usual retention rate. After eight months of outpatient treatment, patients in both treatment groups reported improved quality of life, reduced symptoms of mood disorders and enhanced social adjustment.
One crucial element of this trial was the decision to reprioritize how the goals of treatment were presented to those enrolled in this study. Treatment of newly diagnosed adolescents and young adults tends to focus on weight recovery. For this study, conducted at the University of Sydney, University of London and University of Chicago, treatment goals were set collaboratively, by the care team and the patient, with less emphasis on weight gain and more on quality of life, reduction of mood disorders, and enhanced social adjustment.
"Our goal was to peel back the negative impact of anorexia and to shift the traditional pressure to gain weight to an emphasis on improving quality of life and overall functioning," said the study's lead author Stephen Touyz, PhD, from the Centre for Eating and Dieting Disorders at the University of Sydney. "By refocusing the core of treatment, we were able to engage highly resistant individuals with severe and enduring anorexia nervosa in treatment, circumvent the notoriously high dropout rates and help them make their lives a little better."
Patients with severe and enduring anorexia nervosa (SE-AN) are notoriously difficult to treat. Most of them develop anorexia as adolescents and do not respond to treatment. Participants in this study had suffered from severe anorexia for at least seven years, with an average duration of illness of more than 15 years.
Anorexia nervosa has the highest mortality rate of any psychiatric disorder. Most individuals with SE-AN have been through multiple unsuccessful treatment episodes. Repeated failure leaves them with low motivation and a self image dominated by illness.
After prolonged malnourishment, many of those with SE-AN are disabled and unable to hold a job. They often suffer from neurocognitive, cardiac or liver problems, as well as osteoporosis. Insurance companies frequently refuse to pay for treatment because so few individuals improve.
This study, published online by the journal Psychological Medicine on May 3, 2013, was the first randomized clinical trial for chronic anorexia nervosa. It compared two standard treatments but modified them in ways that made them more suitable for individuals with such a profound and persistent disorder. The treatments—cognitive behavioral therapy (CBT) and specialist supportive clinical management (SSCM)—were altered to focus on retention, improved quality of life and to avoid "further failure experiences."
The researchers enrolled 63 patients, all female, at two clinical centers: at the University of Sydney and St George's Hospital, University of London. The average body mass index of study participants was 16.2, with a range from 11.8 to 18.5. (Normal BMI ranges from 18.5 to 25.) The University of Chicago served as the data-coordinating center.
Thirty-one patients were assigned to CBT and 32 to SSCM. Both treatments involved 30 outpatient therapy sessions over eight months. Patients were assessed at the end of treatment, with follow-up assessments six and 12 months later.
Results from both treatments were comparable, with significant improvements ranging from "moderate" to "large" on many measures. CBT had a greater impact on eating-disorder symptoms and readiness to change. SSCM produced larger improvements in health-related quality of life and depression. Average BMI for both groups increased from 16.2 to 16.8, about 4 percent.
"The results were far better than most people in the field would have expected," said Daniel Le Grange, PhD, professor of psychiatry and director of the eating disorders program at the University of Chicago and the principal investigator for the data-coordinating center. "Many of these patients were profoundly ill. The prevailing wisdom is that current treatments have not been effective and patients are best served by refeeding in the hospital setting. This study showed that specific modification of these behavioral approaches could overcome the high dropout rates and lead to meaningful positive change."
Limitations of the study include a moderate sample size, 63 study participants, and a relatively short follow-up period, 12 months for a disorder that had been present for more than seven years. Despite the limitations, the high retention rate and the magnitude of improvement in most of the outcome measures were very encouraging, especially in the setting of a disorder with poor compliance and limited previous clinical success.
"This study clearly shows that SE-AN patients do respond to, and benefit from, two specialized treatments when done by clinicians with specialist knowledge," the authors wrote. "This study should provide hope for those suffering from severe and enduring AN as well as stimulate interest in the development of new psychosocial treatment approaches."
###
The Australian National Health and Medical Research Council, the NHS Trust (United Kingdom), the Butterfly Foundation (Australia) and the University of Western Sydney funded this study. Additional authors include H. Lacey of St George's Hospital; P. Hay and B. Bamford of the University of Western Sydney; R. Smith and S Macguire of the University of Sydney; K.M. Pike of Columbia University in New York; and R.D. Crosby of the University of North Dakota. The paper, "Treating severe and enduring anorexia nervosa: a randomized clinical trial," can be found at: http://dx.doi.org/10.1017/S0033291713000949.
Rethinking treatment goals improves results for those with persistent anorexia
2013-05-08
ELSE PRESS RELEASES FROM THIS DATE:
Gene offers clues to new treatments for a harmful blood clotting disorder
2013-05-08
A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis -- the formation of a harmful clot in a deep vein. The gene produces an enzyme that, if inhibited via a specific drug therapy, could offer hope to patients prone to deep-vein clots, such as those that sometimes form in the legs during lengthy airplane flights or during recuperation after major surgery. The research, which was led by Yanming Wang, a Penn State University associate professor of biochemistry ...
Human brain cells developed in lab, grow in mice
2013-05-08
A key type of human brain cell developed in the laboratory grows seamlessly when transplanted into the brains of mice, UC San Francisco researchers have discovered, raising hope that these cells might one day be used to treat people with Parkinson's disease, epilepsy, and possibly even Alzheimer's disease, as well as and complications of spinal cord injury such as chronic pain and spasticity.
"We think this one type of cell may be useful in treating several types of neurodevelopmental and neurodegenerative disorders in a targeted way," said Arnold Kriegstein, MD, PhD, ...
Geneticists find causes for severe childhood epilepsies
2013-05-08
Researchers at the University of Arizona have successfully determined the genetic mutations causing severe epilepsies in seven out of 10 children for whom the cause of the disorder could not be determined clinically or by conventional genetic testing.
Instead of sequencing each gene one at a time, the team used a technique called whole-exome sequencing: Rather than combing through all of the roughly 3 billion base pairs of an individual's entire genome, whole-exome-sequencing deciphers only actual genes, and nearly all of them simultaneously.
"My initial hope was that ...
Measuring hidden HIV
2013-05-08
Scientists have long believed that measuring the amount of HIV in a person's blood is an indicator of whether the virus is actively reproducing.
A University of Delaware-led research team reports new evidence that hidden virus replication may be occurring within the body's tissue, despite undetectable virus levels in the blood.
The findings were reported in the Journal of the Royal Society Interface on May 8 in a paper titled "Modelling HIV-1 2-LTR dynamics following raltegravir intensification."
The discovery came after the paper's lead author, Ryan Zurakowski, ...
Bacteria adapt and evade nanosilver's sting -- new study
2013-05-08
Sydney, Australia -- Researchers from the University of New South Wales have cautioned that more work is needed to understand how micro-organisms respond to the disinfecting properties of silver nano-particles, increasingly used in medical and environmental applications.
Although nanosilver has effective antimicrobial properties against certain pathogens, overexposure to silver nano-particles can cause other potentially harmful organisms to rapidly adapt and flourish, a UNSW study reveals.
This result, published in the journal Small, could have wide-reaching implications ...
Differences between 'marathon mice' and 'couch potato mice' reveal key to muscle fitness
2013-05-08
ORLANDO, Fla., May 8, 2013 – Researchers discovered that small pieces of genetic material called microRNAs link the two defining characteristics of fit muscles: the ability to burn sugar and fat and the ability to switch between slow- and fast-twitch muscle fibers. The team used two complementary mouse models—the "marathon mouse" and the "couch potato mouse"—to make this discovery. But what's more, they also found that active people have higher levels of one of these microRNAs than sedentary people. These findings, published May 8 in The Journal of Clinical Investigation, ...
More African-Americans have kidney transplants, but few are from live donors
2013-05-08
SAN DIEGO – While the percentage of kidney transplants involving live donors has remained stable for other minority populations, African Americans have seen a decline in live donors even as more of them receive kidney transplants, according to a study by Henry Ford Hospital in Detroit.
Those findings will be presented May 8 at the annual meeting of the American Urological Association in San Diego.
"African American race has been associated with disparities in care at every step of the kidney transplant process," says Jesse D. Sammon, D.O., a researcher at Henry Ford's ...
Thoracic endografts used successfully to remove tumors invading the aorta
2013-05-08
Minneapolis, MN, May 8, 2013 – Tumors have the potential to grow locally and invade neighboring organs. Some chest tumors may invade one of the great vessels of the body, the aorta. Surgical removal of these tumors is very challenging and necessitates the support of a heart-lung machine. Therefore there is an increased risk of complication and death. In a small series of patients, placing a stent within the aorta facilitated the subsequent removal of tumor and eliminated the need for heart-lung bypass. A report of these results is presented by Stéphane Collaud, MD, MSc, ...
JCI early table of contents for May 8, 2013
2013-05-08
Gene replacement in pigs ameliorates cystic fibrosis-associated intestinal obstruction
Cystic fibrosis (CF) is caused by mutations in CFTR and is characterized by dysfunction of the lungs, liver, pancreas, and intestines. Approximately 15% of babies with CF are born with an obstruction of the small intestine known as meconium ileus, frequently the first sign of CF. Unlike in humans, meconium ileus occurs in 100% of newborn CF pigs. In this issue of the Journal of Clinical Investigation, Michael Welsh and colleagues at the University of Iowa demonstrate that transgenic ...
Gene replacement in pigs ameliorates cystic fibrosis-associated intestinal obstruction
2013-05-08
Cystic fibrosis (CF) is caused by mutations in CFTR and is characterized by dysfunction of the lungs, liver, pancreas, and intestines. Approximately 15% of babies with CF are born with an obstruction of the small intestine known as meconium ileus, frequently the first sign of CF. Unlike in humans, meconium ileus occurs in 100% of newborn CF pigs. In this issue of the Journal of Clinical Investigation, Michael Welsh and colleagues at the University of Iowa demonstrate that transgenic expression of normal CFTR in the intestine of CF pigs alleviated meconium ileus. Over time, ...